Bristol-Myers Squibb vs TCS: Founders, CEOs and History
Bristol-Myers Squibb was founded in 1887 by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers and is led by Christopher Boerner. TCS was founded in 1968 by J.R.D. Tata, F.C. Kohli and is led by K Krithivasan.
Company facts
Bristol-Myers Squibb
- Founded
- 1887
- Headquarters
- Princeton, New Jersey
- Current CEO
- Christopher Boerner
- Employees
- 32,500
TCS
- Founded
- 1968
- Headquarters
- Mumbai, Maharashtra, India
- Current CEO
- K Krithivasan
- Employees
- 593,798
Founders
Bristol-Myers Squibb
Edward Robinson Squibb
Squibb resigned his Navy post and opened a small laboratory in Brooklyn in 1858 to make pure ether, chloroform and other medicines.
William McLaren Bristol
In 1887 Bristol and Myers bought the Clinton Pharmaceutical Company of Clinton, New York, reportedly for about $5,000.
John Ripley Myers
Myers and Bristol bought the Clinton Pharmaceutical Company in Clinton, New York, in 1887 and renamed it Bristol, Myers and Company in 1898.
TCS
J.R.D. Tata
J.R.D. Tata was chairman of Tata Sons from 1938 to 1991. Under his leadership the group set up Tata Computer Centre in 1968, which became Tata Consultancy Services, initially to provide data-processing and management-consultancy services to Tata companies.
F.C. Kohli
Faqir Chand Kohli (1924-2020) moved from Tata Electric Companies to lead TCS in 1969 and served as its first general manager and later CEO until 1996.
CEOs and their tenures
Bristol-Myers Squibb
- Charles A. Heimbold Jr.1994–2001
Chief Executive Officer
Serving as CEO from 1994 to 2001, he aggressively expanded the company's oncology portfolio, notably launching the blockbuster cancer drug Taxol, which drove massive revenue growth.
Source - Peter R. Dolan2001–2006
Chief Executive Officer
Dolan, who had run the consumer products and medical device divisions, succeeded Charles Heimbold in May 2001. His tenure included the ImClone partnership on the cancer drug Erbitux and a federal investigation into wholesaler inventory practices.
Source - James M. Cornelius2006–2010
Chief Executive Officer
Cornelius took over after Peter Dolan's removal in September 2006 and ran the company until May 2010.
Source - Lamberto Andreotti2010–2015
Chief Executive Officer
Andreotti, previously president and chief operating officer, became CEO on May 4, 2010.
Source - Giovanni Caforio2015–2023
Chief Executive Officer
Caforio, a physician, succeeded Lamberto Andreotti in May 2015. He led the $74 billion Celgene acquisition in 2019, the $13.1 billion MyoKardia deal in 2020 and the $4.1 billion Turning Point deal in 2022, and agreed the Mirati purchase in October 2023.
Source - Chris Boerner2023–present
Board Chair and Chief Executive Officer
Boerner became CEO in November 2023 and board chair on April 1, 2024, after serving as executive vice president, chief operating officer and CEO-designate from April 2023 and earlier as chief commercialization officer.
Source
TCS
- F. C. Kohli1969–1996
Co-founder and First CEO
By the time Kohli stepped down from executive responsibility in 1996, TCS-trained programmers numbered in the hundreds of thousands and had helped launch India's broader IT-export industry, earning Kohli the title 'Father of the Indian IT Industry' and India's…
Source - N. Chandrasekaran2009–2017
CEO
He became chairman of Tata Sons in February 2017 and also chairs TCS's board and Air India.
Source - Rajesh Gopinathan2017–2023
CEO and Managing Director
Under Gopinathan, TCS shares nearly tripled, revenue almost doubled, and profit rose about 60% over his six-year tenure -- one of the strongest CEO track records in Indian corporate history.
Source - K. Krithivasan2023–present
CEO and Managing Director
Under Krithivasan, TCS crossed $30 billion in annual revenue in FY2026 and grew its annualized AI revenue run rate to $2.6 billion by Q1 FY2027, even as dollar revenue was roughly flat amid weak discretionary IT spending.
Source
Timeline: Bristol-Myers Squibb and TCS side by side
1858Bristol-Myers Squibb
Edward Robinson Squibb opens his Brooklyn laboratory
Navy surgeon Edward Robinson Squibb started making pure ether and other medicines in Brooklyn. The laboratory burned down on Christmas Eve 1858 and reopened in 1859 after local doctors and surgeons contributed $2,100.
1887Bristol-Myers Squibb
Bristol and Myers buy the Clinton Pharmaceutical Company
Hamilton College graduates William McLaren Bristol and John Ripley Myers bought the Clinton Pharmaceutical Company of Clinton, New York, the business that became Bristol-Myers.
1898Bristol-Myers Squibb
Bristol, Myers and Company is named
The founders renamed the business Bristol, Myers and Company in May 1898. After Myers died in 1899 it became Bristol-Myers, which built national brands in Sal Hepatica and, from 1901, Ipana toothpaste.
1944Bristol-Myers Squibb
Penicillin at wartime scale
Squibb opened what was then the world's largest penicillin plant in New Brunswick, New Jersey. Bristol-Myers had bought Cheplin Biological Laboratories in East Syracuse, New York, in 1943 and converted it to penicillin for Allied forces.
1968TCS
TCS is founded
Tata Consultancy Services begins inside the Tata Group.
1969TCS
F.C. Kohli Joins as First CEO
F.C. Kohli is brought in on deputation to lead TCS, then a 10-consultant operation, and begins building an industrial, assembly-line approach to software delivery.
1989Bristol-Myers Squibb
Bristol-Myers and Squibb merge
Bristol-Myers and Squibb combined to form Bristol-Myers Squibb, uniting a consumer and pharmaceutical company with a research-led drugmaker.
2001TCS
CMC Limited Stake Acquired
TCS acquires a majority stake in CMC Limited from the Government of India, adding systems-integration and public-sector technology capability.
2001TCS
TCS Crosses $1 Billion in Revenue
TCS becomes the first Indian IT services company to cross $1 billion in annual revenue, cementing its position as an industry leader.
2004TCS
TCS lists publicly
TCS completes its IPO and becomes one of India's most important listed technology companies.
2006Bristol-Myers Squibb
CEO Peter Dolan removed over the Plavix deal
After an FBI raid in July 2006 over a patent settlement with generic maker Apotex on the blood thinner Plavix, the federal monitor urged the board to remove CEO Peter Dolan, who stepped down on September 12, 2006.
2009Bristol-Myers Squibb
Medarex bought and Mead Johnson split off
BMS bought Medarex, gaining Yervoy and a share of what became Opdivo, and split off Mead Johnson Nutrition in an exchange offer, completing its shift to a specialty biopharmaceutical company.
2009TCS
TCS crosses major global scale thresholds
TCS expands globally across industries and delivery centers under new then-CEO N. Chandrasekaran.
2011Bristol-Myers Squibb
FDA approves Yervoy
Yervoy (ipilimumab) became the first drug shown to extend overall survival in advanced melanoma, opening BMS's immuno-oncology franchise.
2012Bristol-Myers Squibb
FDA approves Eliquis
The FDA approved Eliquis (apixaban), developed with Pfizer, in December 2012 for stroke prevention in non-valvular atrial fibrillation. It became BMS's largest product, with $14.4 billion of sales in 2025.
2013TCS
N. Chandrasekaran Becomes CEO
Chandrasekaran becomes CEO, leading TCS through a period of rapid international expansion before his 2017 elevation to Tata Sons chairman.
2014Bristol-Myers Squibb
FDA approves Opdivo
The FDA approved the PD-1 inhibitor Opdivo (nivolumab) in December 2014 for advanced melanoma. It reached $10.0 billion of sales in 2025.
2019Bristol-Myers Squibb
Celgene acquisition closes
BMS completed its $74 billion purchase of Celgene on November 20, 2019, adding Revlimid, Pomalyst, Reblozyl and CAR-T programs. Celgene sold Otezla to Amgen for $13.4 billion to win regulatory approval.
2020Bristol-Myers Squibb
MyoKardia deal and a GAAP loss
BMS bought MyoKardia for $13.1 billion, gaining mavacamten (Camzyos). The deal's $11.4 billion in-process R&D charge pushed 2020 to a net loss despite $42.5 billion of revenue.
2020TCS
F.C. Kohli Passes Away
F.C. Kohli, TCS co-founder and first CEO, dies at age 96, having lived to see the company he helped build become one of the worlds largest IT services firms.
2022Bristol-Myers Squibb
Turning Point bought as Revlimid generics arrive
BMS completed the $4.1 billion purchase of Turning Point Therapeutics in August 2022 while volume-limited generic lenalidomide began eroding Revlimid, which had peaked at $12.8 billion in 2021.
2023Bristol-Myers Squibb
Chris Boerner becomes CEO
Chris Boerner succeeded Giovanni Caforio as chief executive in November 2023 and became board chair on April 1, 2024. Weeks earlier BMS had agreed to buy Mirati, and in December it agreed to buy Karuna and RayzeBio.
2023TCS
K. Krithivasan becomes CEO
K. Krithivasan becomes CEO and managing director of TCS, succeeding Rajesh Gopinathan.
2024Bristol-Myers Squibb
Karuna, Mirati and RayzeBio close; Cobenfy approved
The three deals closed between January and March 2024. On September 26, 2024 the FDA approved Cobenfy, the first schizophrenia drug that targets muscarinic rather than dopamine receptors. The Karuna charge produced an $8.9 billion net loss for 2024.
2025Bristol-Myers Squibb
BioNTech partnership, Orbital deal and $48.2B revenue
BMS agreed in June 2025 to co-develop BioNTech's bispecific BNT327 and in October 2025 to buy Orbital Therapeutics for $1.5 billion. Full-year revenue was $48.2 billion with the Growth Portfolio up 17 percent.
2026Bristol-Myers Squibb
Guidance raised and merger reports denied
On July 30, 2026 BMS raised its 2026 revenue guidance to $49.0 to $50.0 billion after second-quarter revenue of $12.97 billion. In August, reports of AstraZeneca merger talks were followed by a senior source telling Reuters there were no discussions.
2026TCS
FY2026 revenue is reported
TCS reports FY2026 revenue of $30.017B and net margin of 19.8%.
2026TCS
Q1 FY2027 AI run-rate grows
TCS reports Q1 FY2027 revenue of $7.624B and annualized AI revenue of $2.6B.
2026TCS
Tata Sons chairman succession opens
On August 12, 2026, N. Chandrasekaran said he would not seek another term as Tata Sons chairman after February 2027; TCS shares fell about 4% on the news.
Acquisitions
Bristol-Myers Squibb
- Orbital Therapeutics2025$1.5B
- Mirati Therapeutics2024$4.8B
- RayzeBio2024$4.1B
- Karuna Therapeutics2024$14B
- Turning Point Therapeutics2022$4.1B
- MyoKardia2020$13.1B
TCS
- W12 Studios2018Undisclosed
- Citigroup Global Services2008$505M
- CMC Limited2001Undisclosed
Questions about Bristol-Myers Squibb vs TCS
Who is the CEO of Bristol-Myers Squibb Company and Tata Consultancy Services Limited?
Bristol-Myers Squibb Company is led by Christopher Boerner and Tata Consultancy Services Limited is led by K Krithivasan. Both serve as the top executive responsible for the company's strategy, operations, and financial performance.
When was Bristol-Myers Squibb Company founded vs Tata Consultancy Services Limited?
Bristol-Myers Squibb Company was founded in 1887 — 81 years before Tata Consultancy Services Limited, which was founded in 1968. Bristol-Myers Squibb Company's longer operating history gives it a deeper track record but also potentially more institutional inertia compared to the younger Tata Consultancy Services Limited.
How many employees does Bristol-Myers Squibb Company have compared to Tata Consultancy Services Limited?
Bristol-Myers Squibb Company employs approximately 32,500 people, while Tata Consultancy Services Limited employs approximately 593,798. Tata Consultancy Services Limited has the larger workforce at 593,798 employees, compared to Bristol-Myers Squibb Company's 32,500. A higher headcount does not necessarily imply greater efficiency — it often reflects differences in business model (e.g., manufacturing vs. software).
Where are Bristol-Myers Squibb Company and Tata Consultancy Services Limited headquartered?
Bristol-Myers Squibb Company is headquartered in United States and Tata Consultancy Services Limited is headquartered in India. Their different home markets mean they may face different regulatory frameworks, tax regimes, and currency exposure.
Who founded Bristol-Myers Squibb Company and Tata Consultancy Services Limited?
Bristol-Myers Squibb Company was founded by Edward Robinson Squibb, William McLaren Bristol, John Ripley Myers. Tata Consultancy Services Limited was founded by J.R.D. Tata, F.C. Kohli.
Which company has a longer operating history — Bristol-Myers Squibb Company or Tata Consultancy Services Limited?
Bristol-Myers Squibb Company has been operating for approximately 139 years, making it the more established of the two companies. Tata Consultancy Services Limited has been in operation for around 58 years. A longer operating history often signals greater institutional resilience and brand recognition, though it can also mean slower adaptation to new market conditions.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bristol-Myers Squibb vs TCS overview